Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Down 9.6% in October

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 30,900 shares, a decrease of 9.6% from the September 30th total of 34,200 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average trading volume of 98,100 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Indaptus Therapeutics in a research note on Wednesday, October 16th.

Indaptus Therapeutics Trading Down 5.6 %

Shares of INDP opened at $1.17 on Friday. The stock has a 50 day moving average of $1.40 and a 200 day moving average of $1.92. Indaptus Therapeutics has a 12 month low of $1.03 and a 12 month high of $3.25. The company has a market capitalization of $11.93 million, a price-to-earnings ratio of -0.63 and a beta of 1.46.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Monday, August 12th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. As a group, equities research analysts predict that Indaptus Therapeutics will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.